| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Sales | 0 | - | - | - |
| Cost of sales | 0 | - | - | - |
| Gross profit | 0 | - | - | - |
| General and administrative | 17,031 | 27,707 | 16,274 | 8,690 |
| Board of directors compensation | 105,750 | 105,750 | 105,750 | 105,750 |
| Total expenses | 122,781 | 133,457 | 122,024 | 114,440 |
| Loss from operations before loss on liability settlement | -122,781 | -133,457 | - | - |
| Loss on liability settlement | 0 | -801,193 | - | - |
| Net loss for the period | -122,781 | -934,650 | -122,024 | -114,440 |
| Basic average shares | - | 32,246,755 | 29,271,755 | 29,271,755 |
| Net loss for the period per common shares - basic | 0 | -0.03 | 0 | 0 |
| Net loss for the period per common shares - diluted | 0 | -0.03 | 0 | 0 |
| Weighted average number of common shares - diluted | 33,521,755 | 32,246,755 | 29,271,755 | 29,271,755 |
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)